Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Some horses 'genetically vulnerable' to sarcoid tumours
horses
"By studying this phenomenon in horses you can learn about human cancer and vice versa."
New research mirrors findings in human studies
 
Genetic differences could help to explain why the papillomavirus behind sarcoid skin tumours affects some horses and not others. A new international study suggests some horses may have a genetic susceptibility to the virus.

Sarcoid skin tumours are the most common type of cancer in horses. Recent research suggests variants of bovine papillomavirus has become adapted to horses and is likely to be the cause of most sarcoids, but little is known about why it affects some horses and not others.

Led by Cornell University, the research group compared the genetic make-up of horses with and without sarcoid tumours. They studied 82 UK and US horses with sarcoid tumours and 272 carefully selected controls that did not have sarcoids.

Looking at more than 50,000 sites in the equine genome, they found that regions on chromosomes 20 and 22 tended to be different in the horses with sarcoids. They say this provides evidence that a horse's genes determine, in part, how vulnerable it is to sarcoids.

The region of chromosome 20 that was associated with sarcoid development is within the part of the genome that is responsible for immune function - the major histocompatibility complex (MHC) class II region. This MHC type is very rare in standardbred horses, which scientists say could explain why sarcoids are diagnosed so infrequently in the breed.

Their research, which has been published in the International Journal of Cancer, mirrors findings in human studies. Tumours caused by human papillomaviruses account for more than 5 per cent of the world's cancer cases. Some people have been shown to have a susceptibility to these viruses, which can cause cervical and other cancers. In women with cervical cancer, a link has also been found with the MHC class II region.

Lead author Dr Doug Antczak said: "That should make a light bulb go off. It suggests there's a common mechanism in both species for susceptibility to tumour progression that may involve subversion of the host immune response. By studying this phenomenon in horses you can learn about human cancer and vice versa."

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.